In the present study we investigated the global survival rates in a cohort of Sardinian patients with lung adenocarcinoma harboring driver genetic alterations in the EGFR, KRAS, BRAF, ALK and MET genes with the aim to examine their real-life impact on survival, and potential correlations with several demographic, life-habit and clinical factors. The gene discussed is EGFR; the disease is lung adenocarcinoma.